ORPHA:199260
Calcifying aponeurotic fibroma
Also known as: Juvenile aponeurotic fibromatosis · Keasby tumor
Publications
372
77.4th percentile
Trials
0
Interventional, condition-specific
Researchers
938
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, superficial fibromatosis characterized by non-malignant, locally invading, fibrosing tumour of differentiated fibroblasts, slowly growing subcutaneously, occurring predominantly distally on the extremities, especially the hands and feet. Histologic examination shows a multinodular pattern with large areas of calcification and fibrosis, and the presence of elongated spindle cells with hyperchromatic plump vesicular nuclei interspersed within fine bands of collagen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016038
- UMLS:C0553647
- NCIT:C4818
Additional Mondo synonyms (4)
Juvenile aponeurotic fibroma · Juvenile aponeurotic fibrosis · Keasby tumour · juvenile aponeurotic fibromatosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
372 matched papers (184 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 4 for broader category fibroma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
372
372 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
372 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
184 in the last 10 years · high confidence · 77.4th percentile (publications denominator)
Phrase hits: 372 · MeSH hits: 0
Who's working on it?
938
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nishio J6 papers · 2026
Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.
Papers in Europe PMC - 02Shinohara Y5 papers · 2026
Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan.
Papers in Europe PMC - 03Antonescu CR4 papers · 2020
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Papers in Europe PMC - 04Aoki M4 papers · 2026
Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Papers in Europe PMC - 05Kao YC4 papers · 2020
Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
Papers in Europe PMC - 06Zhang L4 papers · 2020
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Papers in Europe PMC - 07Chalian M3 papers · 2026
Department of Radiology, University of Washington, Seattle, WA, USA.
Papers in Europe PMC - 08Chijiiwa Y3 papers · 2026
Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan.
Papers in Europe PMC - 09Koga K3 papers · 2026
Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 4 trials are registered for fibroma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
4 interventional trials matched fibroma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: fibroma
4
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05440240·RECRUITING·Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
Conditions: Dupuytren Contracture · Dupuytren's Disease · Contracture · Joint Diseases·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Calcifying aponeurotic fibroma" OR "Juvenile aponeurotic fibromatosis" OR "Keasby tumor" OR "Juvenile aponeurotic fibroma" OR "Juvenile aponeurotic fibrosis" OR "Keasby tumour"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Calcifying aponeurotic fibroma" OR "Juvenile aponeurotic fibromatosis" OR "Keasby tumor" OR "Juvenile aponeurotic fibroma" OR "Juvenile aponeurotic fibrosis" OR "Keasby tumour"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"fibroma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:09:35.151Z